The AHF-CODE preserved study is a prospective, non-randomized, monocenter study performed in patients with heart failure with preserved ejection fraction admitted for worsening heart failure. The main objective of the AHF-CODE preserved study is to identify congestion markers (clinical, biological and ultrasound) at the end of hospitalization for acute heart failure that are associated with the risk of all cause death or rehospitalization for acute heart failure within 3 months of hospital discharge.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
170
Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
Blood sample collection will be performed before discharge from hospital
Telephone interview will be performed at 3, 12 months and 24 months after discharge from Hospital
Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
CHRU de Nancy
Vandœuvre-lès-Nancy, France
RECRUITINGRate of all-cause death
composite endpoint : rate of all-cause death or re-hospitalisation for acute heart failure at 3 months after hospital discharge (with outcome 2 and 3)
Time frame: 3 months after hospital discharge
Rate of re-hospitalisation for acute heart failure
composite endpoint : rate of all-cause death or re-hospitalisation for acute heart failure at 3 months after hospital discharge (with outcome 1 and 3)
Time frame: 3 months after hospital discharge
Rate of day-hospital or in-home IV diuretics injection for acute HF
composite endpoint : rate of all-cause death or re-hospitalisation for acute heart failure at 3 months after hospital discharge (with outcome 2 and 3)
Time frame: 3 months after hospital discharge
Rate of all-cause death
composite endpoint : rate of all-cause death or re-hospitalisation for acute heart failure at 3,12 and 24 months after hospital discharge (with outcome 5)
Time frame: 3, 12 and 24 months after hospital discharge
Rate of re-hospitalisation for acute heart failure
composite endpoint : rate of all-cause death or re-hospitalisation for acute heart failure at 3, 12 and 24 months after hospital discharge (with outcome 4)
Time frame: 3, 12 and 24 months after hospital discharge
rate of day-hospital or in home IV diuretics injection for acute HF
Time frame: 3, 12 and 24 months after hospital discharge
Rate of all-cause death
Rate of all-cause death at 3, 12 and 24 months after hospital discharge
Time frame: 3, 12 and 24 months after hospital discharge
Rate of hospitalisation for acute heart failure
Rate of hospitalisation for acute heart Failure at 3, 12 and 24 months after hospital discharge
Time frame: 3, 12 and 24 months after hospital discharge
Rate of all-cause death
composite endpoint : rate of all-cause death or re-hospitalisation for acute heart failure at 3 months after hospital discharge (with outcome 10)
Time frame: 3, 12 and 24 months after hospital discharge
Rate of hospitalisation for acute heart failure
composite endpoint : rate of all-cause death or re-hospitalisation for acute heart failure at 3 months after hospital discharge (with outcome 9)
Time frame: 3, 12 and 24 months after hospital discharge
Rate of death from all causes
composite endpoint : rate of all-cause death or re-hospitalisation for acute heart failure at 3, 12 and 24 months after hospital discharge (with outcome 12)
Time frame: 3, 12 and 24 months after hospital discharge
Rate of hospitalisation for acute heart failure
composite endpoint : rate of all-cause death or re-hospitalisation for acute heart failure at 3, 12 and 24 months after hospital discharge (with outcome 11)
Time frame: 3, 12 and 24 months after hospital discharge
NYHA (New York Heart Association) class
Time frame: 3, 12 and 24 months after hospital discharge
Natriuretic peptides
BNP or Nt-Pro BNP
Time frame: At inclusion
Renal function assessed by glomerular filtration rate
Time frame: At inclusion
Plasma volume
Calculated from haemoglobin and haematocrit value
Time frame: At inclusion
Blood potassium
Time frame: At inclusion
Liver elastography value
Measured with Fibroscan®
Time frame: At inclusion
Quality of life assessed by Kansas City Cardiomyopathy Questionnaire
Assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ)
Time frame: At inclusion and 3, 6 and 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.